Gynecologic CancersCHeMoONNCT07483905
Interest in Nighttime Day Hospital Chemotherapy Infusions Among Gynecologic Cancer Patients
An observational study of Gynecologic Cancers, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
Trial summary
This observational study aims to assess the interest of patients with gynecologic cancers in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gynecologic Cancers
- What is being tested?
- online survey
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- How many people
- 200 participants
- Where
- 1 siteItaly
- Study dates
- 12 Mar 2026to 1 Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Patients with gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions.
Who may be able to join
- Female patients
- aged 18 years or older
- Diagnosis of a gynecologic cancer
- Receiving care at the participating institution
- Ability to independently understand and complete complete the anonymous online survey
Who cannot join
- Inability to access or complete the online questionnaire or difficulty with reading and writing
- Cognitive impairment
- Patients currently hospitalized or in emergency settings.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Serena Maria Boccia contact
About this study
Official title: Assessment of Interest Among Patients With Gynecologic Cancers in a Nighttime Day Hospital (DH) Service for Long-duration Chemotherapy Infusions: an Observational Study Based on an Anonymous Online Survey.
This observational study aims to assess the interest of patients with gynecologic cancers in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. An anonymous online survey will be distributed to eligible patients to evaluate their preferences, perceived benefits, and potential barriers related to receiving chemotherapy during nighttime hours. The results of this study will help inform the feasibility and acceptability of implementing a nighttime Day Hospital service for prolonged chemotherapy infusions.
Read the detailed description
Long-duration chemotherapy infusions are increasingly used in the treatment of gynecologic cancers. These treatments often require prolonged administration times that may extend over several hours and may affect patients' daily activities and quality of life when delivered during standard daytime hospital schedules. The implementation of a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions could represent an alternative organizational model aimed at improving patient convenience and optimizing hospital resource utilization. However, the acceptability of such a service from the patients' perspective has not been well explored.
This observational study will evaluate the interest and perceived acceptability of a nighttime Day Hospital service among patients with gynecologic cancers who may receive long-duration chemotherapy infusions. Data will be collected through an anonymous online survey administered to eligible patients. The questionnaire will explore patient preferences, potential advantages and disadvantages, logistical considerations, and willingness to receive chemotherapy during nighttime hours.
The results of this study may provide preliminary information on patient perspectives and help inform future organizational strategies for the delivery of prolonged chemotherapy infusions.
- Conditions
- Gynecologic Cancers
- Being tested
- online survey
- Keywords
- Long-duration Chemotherapy, Nighttime Day Hospital, Cancer Care Organization, Patient Preferences
- Medical subject headings
- Patient Preference
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
online surveyBehavioural
Participants will complete an anonymous online survey designed to assess their interest in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions.
| Study group | Role | What they receive |
|---|---|---|
| Patients with gynecologic cancers | Patients affected by gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions. Receives: Behavioral: online survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Level of patient interest in a nighttime Day Hospital service for long-duration chemotherapy infusions
Assessment of the level of interest among patients with gynecologic cancers in receiving long-duration chemotherapy infusions during nighttime hours in a Day Hospital setting, as evaluated through responses to an anonymous online survey.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start12 Mar 2026 (estimated)
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gynecologic CancersStudies of the same condition, open and under way.
- More trials run by Fondazione Policlinico Universitario Agostino Gemelli IRCCSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, FAGOTTI ANNA, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Investigators
- Anna Fagotti, Principal investigator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07483905
- Sponsor's protocol ID
- 26945
- Other IDs
- Study ID 26945
- Acronym
- CHeMoON
- Status last verified
- Mar 2026
- First submitted
- 12 Mar 2026
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Interest Among Patients With Gynecologic Cancers in a Nighttime Day Hospital (DH) Service for Long-duration Chemotherapy Infusions: an Observational Study Based on an Anonymous Online Survey.
- ClinicalTrials.gov ID
- NCT07483905
- Acronym / sponsor ID
- CHeMoON / 26945
- Conditions
- Gynecologic Cancers
- Keywords
- Long-duration Chemotherapy, Nighttime Day Hospital, Cancer Care Organization, Patient Preferences
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversity, hospital or other
- Study start
- 12 Mar 2026 (estimated)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 1 Jul 2026 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study aims to assess the interest of patients with gynecologic cancers in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. An anonymous online survey will be distributed to eligible patients to evaluate their preferences, perceived benefits, and potential barriers related to receiving chemotherapy during nighttime hours. The results of this study will help inform the feasibility and acceptability of implementing a nighttime Day Hospital service for prolonged chemotherapy infusions.
Detailed description
Long-duration chemotherapy infusions are increasingly used in the treatment of gynecologic cancers. These treatments often require prolonged administration times that may extend over several hours and may affect patients' daily activities and quality of life when delivered during standard daytime hospital schedules. The implementation of a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions could represent an alternative organizational model aimed at improving patient convenience and optimizing hospital resource utilization. However, the acceptability of such a service from the patients' perspective has not been well explored.
This observational study will evaluate the interest and perceived acceptability of a nighttime Day Hospital service among patients with gynecologic cancers who may receive long-duration chemotherapy infusions. Data will be collected through an anonymous online survey administered to eligible patients. The questionnaire will explore patient preferences, potential advantages and disadvantages, logistical considerations, and willingness to receive chemotherapy during nighttime hours.
The results of this study may provide preliminary information on patient perspectives and help inform future organizational strategies for the delivery of prolonged chemotherapy infusions.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with gynecologic cancers | – | Behavioral: online surveyPatients affected by gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with gynecologic cancers receiving care at the participating institution who are invited to complete an anonymous online survey assessing their interest in a nighttime Day Hospital service for long-duration chemotherapy infusions.
Key inclusion criteria (5 listed)
- Female patients
- aged 18 years or older
- Diagnosis of a gynecologic cancer
- Receiving care at the participating institution
- Ability to independently understand and complete complete the anonymous online survey
Key exclusion criteria (3 listed)
- Inability to access or complete the online questionnaire or difficulty with reading and writing
- Cognitive impairment
- Patients currently hospitalized or in emergency settings.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| online surveyParticipants will complete an anonymous online survey designed to assess their interest in a nighttime Day Hospital service for the administration of long-duration chemotherapy infusions. | Behavioural | Patients with gynecologic cancers |
Primary outcome
Level of patient interest in a nighttime Day Hospital service for long-duration chemotherapy infusions
Time frame: Baseline
Assessment of the level of interest among patients with gynecologic cancers in receiving long-duration chemotherapy infusions during nighttime hours in a Day Hospital setting, as evaluated through responses to an anonymous online survey.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Gynecologic Cancers
RecruitingPhase 2
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Recruiting
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
Breast Cancer, Corpus Uteri Cancer
Not yet recruiting
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Non Small Cell Lung Cancer, Melanoma (Skin Cancer)
Enrolling by invitation
Peer Ambassador in Gyn Onc Trials
Ovarian Cancer
Active, not recruitingPhase 2
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
Ovarian Clear Cell Carcinoma, Gynecologic Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Serena Maria Boccia contact
Anna Fagotti principal investigator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gynecologic Cancers, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anna Fagotti (+390630153502, anna.fagotti@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Level of patient interest in a nighttime Day Hospital service for long-duration chemotherapy infusions (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.